These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36403719)

  • 1. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
    Roskoski R
    Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
    Roskoski R
    Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
    Roskoski R
    Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
    Roskoski R
    Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes.
    Roskoski R
    Pharmacol Res; 2021 Jul; 169():105660. PubMed ID: 33971270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
    Roskoski R
    Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
    De SK
    Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.